Individual Stock News 1. Concord New Energy (00182.HK) signed a power purchase agreement with Tesla. 2. Huaxida (00901.HK) issued a profit warning: expecting interim net profit to increase by 70% to 80% year-on-year. 3. GigaDevice (03986.HK) and M

2026-08-03

Individual Stock News 1. Concord New Energy (00182.HK) signed a power purchase agreement with Tesla. 2. Huaxida (00901.HK) issued a profit warning: expecting interim net profit to increase by 70% to 80% year-on-year. 3. GigaDevice (03986.HK) and Montage Technology (06809.HK) were added to the Hang Seng China Enterprises Index. 4. Shanghai Auntie (02589.HK) announced interim results: adjusted profit of approximately RMB 345 million, an increase of 41.6% year-on-year. 5. Ingdan Innovation (00400.HK) expects first-half revenue of approximately RMB 12 billion to RMB 14 billion, an increase of 80% to 100% year-on-year. 6. Hygon Semiconductor (01191.HK) has finalized chip procurement arrangements for 2027 with upstream independent third-party core chip suppliers. 7. Rico Bio-B (02179.HK) issued a profit warning: It expects a loss attributable to shareholders of RMB 201-222 million for the first half of the year, narrowing by approximately 34.71% to 40.93% year-on-year. 8. Xinyi Glass (00868.HK) announced its interim results: Profit attributable to equity holders is approximately RMB 1.184 billion, a year-on-year increase of 16.9%, with a dividend of HKD 0.15 per share. 9. Xunze (03317.HK) issued a profit alert: It expects a significant year-on-year increase in revenue of approximately 388.76% for the first half of the year, with adjusted net profit of approximately RMB 67 million, turning a loss into a profit compared to the same period last year. 10. Lenovo Holdings (03396.HK): It expects net profit of no less than RMB 2 billion for the first half of this year, an increase of 186% year-on-year. 11. Huanghe Industry (00318.HK): The publication of its 2026 full-year results has been postponed, and trading in its shares is suspended. 12. Insilicon Technologies (03696.HK): ISM8969/HT-001 has been approved by the National Medical Products Administration for clinical trials of new drugs for the treatment of Parkinson's disease.